Melanoma (Skin)

Effectiveness of Group and Individual Training in EFT for Patients in Remission From Melanoma

Fianlimab&Cemiplimab as TotalNeoadj The (TNT) ForMelanoma

High-Intensity Exercise and High-Fiber Diet for Immunotherapy Outcomes in Melanoma Patients: The DUO Trial

Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma

AI-based Medical Device Validation for Early Melanoma Detection

Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma

A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors

High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma

Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma

Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases

A Prospective Observational Study on Targeted Therapy for Unresectable or Metastatic BRAFV600E Mutant Melanoma Patients

Nivolumab in Treating Patients With Stage IIB-IIC Melanoma That Can Be Removed by Surgery

Study of Alterations in Tumor Metabolism Associated With the Development of Immunotherapy Resistance in Melanoma

SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study)

Using MC1R Genotype to Impact Melanoma Risk Behavior

Pembrolizumab and EDP1503 in Advanced Melanoma

Cryotherapy With in Situ Immunotherapy in Melanoma Metastasis

Zr89 + PET Companion Trial

START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer

A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1).